PeakShares LLC Invests $528,000 in Merck & Co., Inc. $MRK

PeakShares LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,018 shares of the company’s stock, valued at approximately $528,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. during the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. IFC & Insurance Marketing Inc. purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $31,000. Finally, High Note Wealth LLC boosted its stake in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. UBS Group increased their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Finally, Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $128.18.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $114.04 on Friday. The firm has a market capitalization of $281.65 billion, a price-to-earnings ratio of 32.12, a price-to-earnings-growth ratio of 2.56 and a beta of 0.21. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The business’s 50 day simple moving average is $115.94 and its 200-day simple moving average is $113.60. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The firm had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period last year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts forecast that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 3.0%. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.